Opus Genetics (IRD) financial statements
Opus Genetics reported revenue of $14M in fiscal 2025, up 29.6% a year over 6 years.
Net income was -$50M.
The diluted share count rose 186% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Opus Genetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3M | $0 | $589,000 | $40M | $19M | $11M | $14M |
| Research and development | $10M | $11M | $13M | $5M | $7M | $15M | $14M | $18M | $27M | $31M |
| Selling, general and admin | $6M | $7M | $7M | $2M | $3M | $8M | $7M | $12M | $18M | $22M |
| Operating income | -$16M | -$17M | -$21M | -$4M | -$20M | -$23M | $18M | -$11M | -$62M | -$39M |
| Interest expense | — | — | — | $1M | $7M | $2,000 | $9,000 | $0 | $0 | $129,000 |
| Pre-tax income | -$9M | -$25M | -$14M | -$6M | -$25M | -$57M | $18M | -$10M | -$58M | -$50M |
| Income tax | — | — | — | $0 | $0 | $0 | $315,000 | $12,000 | $0 | $0 |
| Net income | -$9M | -$25M | -$14M | -$6M | -$25M | -$57M | $18M | -$10M | -$58M | -$50M |
| EPS (diluted) | -$0.43 | -$0.92 | -$5.25 | -$2.17 | -$5.28 | -$3.82 | $0.87 | -$0.46 | -$2.15 | -$0.80 |
| Diluted shares | 22M | 27M | 3M | 3M | 5M | 15M | 21M | 22M | 27M | 62M |
| Operating margin | — | — | — | -139.8% | — | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Net margin | — | — | — | -205.6% | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
Balance sheet
Fiscal years, from Opus Genetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $20M | $27M | $15M | $12M | $16M | $25M | $43M | $51M | $30M | $45M |
| Receivables | — | — | — | — | $0 | $0 | $1M | $926,000 | $4M | $2M |
| Total current assets | $21M | $28M | $16M | $2M | $18M | $26M | $49M | $54M | $37M | $50M |
| Property, plant and equipment | $88,650 | $121,460 | $112,473 | $22,000 | $14,000 | $10,000 | $6,000 | $0 | $252,000 | $199,000 |
| Total assets | $21M | $28M | $16M | $2M | $18M | $26M | $49M | $54M | $37M | $50M |
| Total current liabilities | — | — | $3M | $9M | $3M | $4M | $3M | $4M | $11M | $8M |
| Long-term debt | — | — | — | — | — | — | — | — | $0 | $1M |
| Total liabilities | $4M | $12M | $5M | $9M | $31M | $4M | $3M | $4M | $11M | $35M |
| Shareholders' equity | $17M | $17M | -$2M | -$8M | -$13M | $22M | $46M | $50M | $7M | $15M |
| Net debt | -$12M | -$9M | -$9M | -$2M | -$16M | -$25M | -$43M | -$51M | -$30M | -$44M |
Cash flow
Fiscal years, from Opus Genetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13M | -$15M | -$19M | -$4M | -$7M | -$19M | $14M | -$1M | -$26M | -$35M |
| Capital spending | — | — | — | $25,000 | $0 | — | — | — | — | — |
| Free cash flow | — | — | — | -$4M | -$7M | — | — | — | — | — |
| Stock-based compensation | $1M | $1M | $1M | $308,000 | $2M | $2M | $2M | $4M | $3M | $3M |
| Free cash flow margin | — | — | — | -120.6% | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IRD.
Open IRD in InvestinglyQuestions
What was Opus Genetics's revenue in 2025?
$14M in fiscal 2025, from its 10-K filing.
From Opus Genetics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.